[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a complex scenario: ARDS on VV-ECMO with suspected HIT (4T score 6) requiring argatroban anticoagulation, complicated by significant hemolysis (plasma free Hb 800 mg/dL). Key discriminating findings: (1) argatroban is a direct thrombin inhibitor, (2) severe hemolysis interferes with clot-based assays, (3) ECMO causes consumptive coagulopathy and factor depletion. The question asks which assay most reliably monitors argatroban in this setting. Anti-IIa chromogenic assay (C) directly measures thrombin inhibition and is minimally affected by hemolysis, factor deficiencies, or platelet abnormalities—making it ideal for this scenario. aPTT (A) is unreliable due to hemolysis interference and factor consumption. Anti-Xa (B) measures factor Xa inhibition, not thrombin inhibition, so it's inappropriate for argatroban. ACT (D) is affected by platelet count and fibrinogen levels. dRVVT (E) is for lupus anticoagulant screening, not anticoagulant monitoring. The keyed answer is medically accurate and represents current best practice for monitoring direct thrombin inhibitors in complex ECMO scenarios with hemolysis. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a complex scenario: ARDS on VV-ECMO with suspected HIT (4T score 6) requiring argatroban anticoagulation, complicated by significant hemolysis (plasma free Hb 800 mg/dL). Key discriminating findings: (1) argatroban is a direct thrombin inhibitor, (2) severe hemolysis interferes with clot-based assays, (3) ECMO causes consumptive coagulopathy and factor depletion. The question asks which assay most reliably monitors argatroban in this setting. Anti-IIa chromogenic assay (C) directly measures thrombin inhibition and is minimally affected by hemolysis, factor deficiencies, or platelet abnormalities—making it ideal for this scenario. aPTT (A) is unreliable due to hemolysis interference and factor consumption. Anti-Xa (B) measures factor Xa inhibition, not thrombin inhibition, so it's inappropriate for argatroban. ACT (D) is affected by platelet count and fibrinogen levels. dRVVT (E) is for lupus anticoagulant screening, not anticoagulant monitoring. The keyed answer is medically accurate and represents current best practice for monitoring direct thrombin inhibitors in complex ECMO scenarios with hemolysis. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presenting with classic thrombotic microangiopathy (TMA) features: AKI, thrombocytopenia, schistocytes, elevated LDH, low haptoglobin. The key discriminating finding is ADAMTS13 activity 35% (not severely deficient), which excludes TTP (requires <10%). This, combined with gemcitabine exposure, points to drug-induced TMA. Option C (discontinue gemcitabine + supportive care) is the correct management for drug-induced TMA. Option A (plasma exchange) is indicated for TTP with severe ADAMTS13 deficiency, not present here. Option B (eculizumab) treats complement-mediated atypical HUS, not drug-induced TMA. Option D (rituximab) is adjunctive therapy for refractory TTP. Option E (caplacizumab) is for TTP with severe ADAMTS13 deficiency. The stem provides sufficient discriminating data (ADAMTS13 level, drug exposure) to identify a unique best answer. Medical accuracy is excellent: gemcitabine-induced TMA management requires immediate drug cessation, and the ADAMTS13 threshold correctly excludes TTP. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presenting with classic thrombotic microangiopathy (TMA) features: AKI, thrombocytopenia, schistocytes, elevated LDH, low haptoglobin. The key discriminating finding is ADAMTS13 activity 35% (not severely deficient), which excludes TTP (requires <10%). This, combined with gemcitabine exposure, points to drug-induced TMA. Option C (discontinue gemcitabine + supportive care) is the correct management for drug-induced TMA. Option A (plasma exchange) is indicated for TTP with severe ADAMTS13 deficiency, not present here. Option B (eculizumab) treats complement-mediated atypical HUS, not drug-induced TMA. Option D (rituximab) is adjunctive therapy for refractory TTP. Option E (caplacizumab) is for TTP with severe ADAMTS13 deficiency. The stem provides sufficient discriminating data (ADAMTS13 level, drug exposure) to identify a unique best answer. Medical accuracy is excellent: gemcitabine-induced TMA management requires immediate drug cessation, and the ADAMTS13 threshold correctly excludes TTP. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes acute barium carbonate poisoning with classic triad of GI symptoms, profound hypokalemia (2.1 mEq/L), and muscle weakness. Key discriminating findings: (1) temporal relationship to barium ingestion, (2) severe hypokalemia with ECG changes, (3) muscle weakness indicating functional potassium deficit despite normal total body stores. Barium's unique mechanism is blockade of voltage-gated potassium channels (Kv), trapping K+ intracellularly and creating paradoxical hypokalemia. Option B correctly identifies both mechanism (intracellular shift via K+ channel blockade) and elimination strategy (oral sodium sulfate to precipitate residual barium as insoluble BaSO4). Option A is incorrect because hemodialysis is ineffective for barium due to large volume of distribution. Options C, D, E describe mechanisms unrelated to barium toxicity. The item is medically accurate regarding barium's pathophysiology and management. No logical flaws exist; stem provides sufficient detail to identify unique best answer. Medical accuracy is excellent with precise mechanism and evidence-based treatment. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes acute barium carbonate poisoning with classic triad of GI symptoms, profound hypokalemia (2.1 mEq/L), and muscle weakness. Key discriminating findings: (1) temporal relationship to barium ingestion, (2) severe hypokalemia with ECG changes, (3) muscle weakness indicating functional potassium deficit despite normal total body stores. Barium's unique mechanism is blockade of voltage-gated potassium channels (Kv), trapping K+ intracellularly and creating paradoxical hypokalemia. Option B correctly identifies both mechanism (intracellular shift via K+ channel blockade) and elimination strategy (oral sodium sulfate to precipitate residual barium as insoluble BaSO4). Option A is incorrect because hemodialysis is ineffective for barium due to large volume of distribution. Options C, D, E describe mechanisms unrelated to barium toxicity. The item is medically accurate regarding barium's pathophysiology and management. No logical flaws exist; stem provides sufficient detail to identify unique best answer. Medical accuracy is excellent with precise mechanism and evidence-based treatment. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The question asks for the \\\"most specific diagnosis\\\" for GAMT deficiency. Key stem clues: 3-month-old with intractable seizures, hypotonia, developmental regression, bilateral globus pallidus hyperintensity on MRI, and low plasma creatine - classic presentation of cerebral creatine deficiency syndrome. Main logical issue: While CSF guanidinoacetate is elevated in GAMT deficiency, GAMT gene sequencing (option D) provides THE definitive, most specific diagnosis by directly identifying pathogenic variants in the GAMT gene itself. Biochemical markers (plasma/CSF/urine GAA) are screening tools that suggest the diagnosis but are not as specific as molecular genetic confirmation. The rationale's claim that \\\"sequencing may miss deep intronic variants or large deletions\\\" applies to all genetic testing but doesn't negate that it remains the gold standard for definitive diagnosis. Medical accuracy issue: The item conflates \\\"most sensitive biomarker\\\" with \\\"most specific diagnosis.\\\" CSF GAA is indeed a sensitive biomarker, but genetic testing provides the most specific diagnosis. Minimal fix: Change the key to D (GAMT gene sequencing) OR rephrase the question to ask for \\\"most sensitive biomarker\\\" rather than \\\"most specific diagnosis.\\\"\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The question asks for the \"most specific diagnosis\" for GAMT deficiency. Key stem clues: 3-month-old with intractable seizures, hypotonia, developmental regression, bilateral globus pallidus hyperintensity on MRI, and low plasma creatine - classic presentation of cerebral creatine deficiency syndrome. Main logical issue: While CSF guanidinoacetate is elevated in GAMT deficiency, GAMT gene sequencing (option D) provides THE definitive, most specific diagnosis by directly identifying pathogenic variants in the GAMT gene itself. Biochemical markers (plasma/CSF/urine GAA) are screening tools that suggest the diagnosis but are not as specific as molecular genetic confirmation. The rationale's claim that \"sequencing may miss deep intronic variants or large deletions\" applies to all genetic testing but doesn't negate that it remains the gold standard for definitive diagnosis. Medical accuracy issue: The item conflates \"most sensitive biomarker\" with \"most specific diagnosis.\" CSF GAA is indeed a sensitive biomarker, but genetic testing provides the most specific diagnosis. Minimal fix: Change the key to D (GAMT gene sequencing) OR rephrase the question to ask for \"most sensitive biomarker\" rather than \"most specific diagnosis.\"", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old with progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, gait ataxia over 18 months, and CSF lymphocytic pleocytosis. Key discriminating findings are the combination of sleep disorders (non-REM parasomnia + OSA), bulbar dysfunction, ataxia, and subacute-chronic progression. This constellation is pathognomonic for anti-IgLON5 disease. The keyed answer (C) correctly identifies anti-IgLON5 antibody and tau deposition in brainstem/hypothalamus, which is the unique pathological hallmark distinguishing this from other autoimmune encephalitides. Alternative A (anti-Hu) presents with sensory neuropathy and paraneoplastic features, not this sleep-bulbar syndrome. Option B (anti-NMDA receptor) typically affects younger patients with psychiatric symptoms and movement disorders, not this specific sleep phenotype. Option D (anti-LGI1) is characterized by faciobrachial dystonic seizures and hyponatremia, not parasomnia. Option E (anti-GAD65) causes stiff-person syndrome or cerebellar ataxia without the sleep-bulbar complex. The item is medically accurate, reflecting current understanding that anti-IgLON5 is a unique tauopathy-associated autoimmune disorder. No fix needed; the question effectively tests recognition of this rare but distinctive syndrome.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old with progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, gait ataxia over 18 months, and CSF lymphocytic pleocytosis. Key discriminating findings are the combination of sleep disorders (non-REM parasomnia + OSA), bulbar dysfunction, ataxia, and subacute-chronic progression. This constellation is pathognomonic for anti-IgLON5 disease. The keyed answer (C) correctly identifies anti-IgLON5 antibody and tau deposition in brainstem/hypothalamus, which is the unique pathological hallmark distinguishing this from other autoimmune encephalitides. Alternative A (anti-Hu) presents with sensory neuropathy and paraneoplastic features, not this sleep-bulbar syndrome. Option B (anti-NMDA receptor) typically affects younger patients with psychiatric symptoms and movement disorders, not this specific sleep phenotype. Option D (anti-LGI1) is characterized by faciobrachial dystonic seizures and hyponatremia, not parasomnia. Option E (anti-GAD65) causes stiff-person syndrome or cerebellar ataxia without the sleep-bulbar complex. The item is medically accurate, reflecting current understanding that anti-IgLON5 is a unique tauopathy-associated autoimmune disorder. No fix needed; the question effectively tests recognition of this rare but distinctive syndrome.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The question describes a VV-ECMO circuit with extensive air and a pulseless patient. Key discriminating findings: (1) VV-ECMO configuration (venous-to-venous), (2) extensive air in circuit, (3) patient pulseless (cardiac arrest). The critical error in the rationale is the claim that 'air embolism is venous' in VV-ECMO. In VV-ECMO, oxygenated blood returns to the venous system (right atrium), passes through the right heart, and enters pulmonary circulation. Massive air can cause pulmonary artery air lock and obstructive shock, but can also paradoxically embolize systemically if a PFO exists or overwhelm pulmonary filtration. A pulseless patient requires immediate CPR per ACLS protocols - this is the priority. Option B (clamping/aspirating) addresses the circuit but ignores the pulseless state. Option D correctly prioritizes CPR while providing 100% oxygen. The rationale incorrectly states 'CPR is secondary to circuit management' - this contradicts basic resuscitation principles where circulation takes precedence. Medical accuracy issue: The teaching point misrepresents VV-ECMO air embolism pathophysiology and deprioritizes life-saving CPR. Minimal fix: Change key to D, or reframe question to ask about circuit management specifically (not immediate management of pulseless patient).\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is incorrect. The question describes a VV-ECMO circuit with extensive air and a pulseless patient. Key discriminating findings: (1) VV-ECMO configuration (venous-to-venous), (2) extensive air in circuit, (3) patient pulseless (cardiac arrest). The critical error in the rationale is the claim that 'air embolism is venous' in VV-ECMO. In VV-ECMO, oxygenated blood returns to the venous system (right atrium), passes through the right heart, and enters pulmonary circulation. Massive air can cause pulmonary artery air lock and obstructive shock, but can also paradoxically embolize systemically if a PFO exists or overwhelm pulmonary filtration. A pulseless patient requires immediate CPR per ACLS protocols - this is the priority. Option B (clamping/aspirating) addresses the circuit but ignores the pulseless state. Option D correctly prioritizes CPR while providing 100% oxygen. The rationale incorrectly states 'CPR is secondary to circuit management' - this contradicts basic resuscitation principles where circulation takes precedence. Medical accuracy issue: The teaching point misrepresents VV-ECMO air embolism pathophysiology and deprioritizes life-saving CPR. Minimal fix: Change key to D, or reframe question to ask about circuit management specifically (not immediate management of pulseless patient).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes severe steroid-refractory ICANS (grade 4: status epilepticus, cerebral edema) after CAR-T therapy. Key discriminating findings: day 12 post-axicabtagene ciloleucel, status epilepticus, cerebral edema, failed methylprednisolone 1 g/day × 3 days. The keyed answer (anakinra, IL-1 blockade) represents emerging investigational therapy for steroid-refractory ICANS, but this is NOT established standard-of-care per current ASTCT 2024 guidelines. Tocilizumab (option C) is explicitly recommended for CRS but contraindicated/not recommended for isolated ICANS due to concerns about worsening neurotoxicity. However, the evidence base for anakinra in steroid-refractory ICANS consists primarily of case reports and small series—it is not FDA-approved or guideline-endorsed for this indication. The item requires test-takers to know cutting-edge investigational protocols rather than established management algorithms. Main logical issue: The question assumes anakinra is 'most appropriate' without sufficient consensus evidence, making this a knowledge-level question about experimental therapy rather than standard practice. Main medical accuracy issue: Presenting investigational therapy as definitive 'most appropriate' overstates current evidence. Minimal fix: Reframe as 'Which investigational agent has been reported for steroid-refractory ICANS?' or provide more context about institutional protocols.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes severe steroid-refractory ICANS (grade 4: status epilepticus, cerebral edema) after CAR-T therapy. Key discriminating findings: day 12 post-axicabtagene ciloleucel, status epilepticus, cerebral edema, failed methylprednisolone 1 g/day × 3 days. The keyed answer (anakinra, IL-1 blockade) represents emerging investigational therapy for steroid-refractory ICANS, but this is NOT established standard-of-care per current ASTCT 2024 guidelines. Tocilizumab (option C) is explicitly recommended for CRS but contraindicated/not recommended for isolated ICANS due to concerns about worsening neurotoxicity. However, the evidence base for anakinra in steroid-refractory ICANS consists primarily of case reports and small series—it is not FDA-approved or guideline-endorsed for this indication. The item requires test-takers to know cutting-edge investigational protocols rather than established management algorithms. Main logical issue: The question assumes anakinra is 'most appropriate' without sufficient consensus evidence, making this a knowledge-level question about experimental therapy rather than standard practice. Main medical accuracy issue: Presenting investigational therapy as definitive 'most appropriate' overstates current evidence. Minimal fix: Reframe as 'Which investigational agent has been reported for steroid-refractory ICANS?' or provide more context about institutional protocols.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes severe calcium channel blocker (CCB) toxicity with refractory shock and bradycardia after massive sustained-release verapamil ingestion. Key discriminating findings: 10g verapamil overdose (massive), refractory shock (BP 70/40), bradycardia (HR 40), and HIET initiation. The question asks for optimal insulin dosing and monitoring frequency. Option B (1-10 units/kg/hr with hourly glucose checks) correctly reflects established HIET protocols for severe CCB toxicity. This supraphysiologic insulin dosing overcomes insulin resistance and enhances myocardial contractility. Hourly glucose monitoring is critical to prevent hypoglycemia during concurrent dextrose infusion. Option A uses subtherapeutic insulin doses. Option C focuses on potassium rather than glucose monitoring. Options D and E exceed standard maximum dosing (>10 units/kg/hr) and monitor wrong parameters. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, consistent with toxicology guidelines and critical care standards for CCB overdose management. No contradictions or underspecification present. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes severe calcium channel blocker (CCB) toxicity with refractory shock and bradycardia after massive sustained-release verapamil ingestion. Key discriminating findings: 10g verapamil overdose (massive), refractory shock (BP 70/40), bradycardia (HR 40), and HIET initiation. The question asks for optimal insulin dosing and monitoring frequency. Option B (1-10 units/kg/hr with hourly glucose checks) correctly reflects established HIET protocols for severe CCB toxicity. This supraphysiologic insulin dosing overcomes insulin resistance and enhances myocardial contractility. Hourly glucose monitoring is critical to prevent hypoglycemia during concurrent dextrose infusion. Option A uses subtherapeutic insulin doses. Option C focuses on potassium rather than glucose monitoring. Options D and E exceed standard maximum dosing (>10 units/kg/hr) and monitor wrong parameters. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, consistent with toxicology guidelines and critical care standards for CCB overdose management. No contradictions or underspecification present. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - WASP gene sequencing is the correct best answer, not flow cytometry. The clinical vignette describes classic Wiskott-Aldrich syndrome (WAS): male infant with eczema, thrombocytopenia with small platelets, recurrent infections, and petechiae. Key discriminating findings: X-linked pattern (male), triad of immunodeficiency + eczema + thrombocytopenia with microthrombocytes. The question asks for the \\\"most sensitive\\\" diagnostic test. WASP gene sequencing (Option A) is the gold standard and most sensitive test, detecting >95% of mutations including point mutations, deletions, insertions, and splice site variants. Modern sequencing techniques (including deletion/duplication analysis) capture virtually all pathogenic variants. Flow cytometry for WASP protein expression (Option D, the keyed answer) has limitations: it may show normal or reduced (not absent) expression in some mutations, particularly missense variants that produce dysfunctional protein. It is useful for rapid screening but less sensitive than comprehensive genetic testing. The rationale incorrectly claims sequencing \\\"may miss\\\" variants that modern NGS panels routinely detect. Medical accuracy issue: The explanation misrepresents current molecular diagnostic capabilities. Minimal fix: Change the correct answer key from D to A, or reframe the question to ask for \\\"most rapid screening test\\\" if flow cytometry is the intended answer.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - WASP gene sequencing is the correct best answer, not flow cytometry. The clinical vignette describes classic Wiskott-Aldrich syndrome (WAS): male infant with eczema, thrombocytopenia with small platelets, recurrent infections, and petechiae. Key discriminating findings: X-linked pattern (male), triad of immunodeficiency + eczema + thrombocytopenia with microthrombocytes. The question asks for the \"most sensitive\" diagnostic test. WASP gene sequencing (Option A) is the gold standard and most sensitive test, detecting >95% of mutations including point mutations, deletions, insertions, and splice site variants. Modern sequencing techniques (including deletion/duplication analysis) capture virtually all pathogenic variants. Flow cytometry for WASP protein expression (Option D, the keyed answer) has limitations: it may show normal or reduced (not absent) expression in some mutations, particularly missense variants that produce dysfunctional protein. It is useful for rapid screening but less sensitive than comprehensive genetic testing. The rationale incorrectly claims sequencing \"may miss\" variants that modern NGS panels routinely detect. Medical accuracy issue: The explanation misrepresents current molecular diagnostic capabilities. Minimal fix: Change the correct answer key from D to A, or reframe the question to ask for \"most rapid screening test\" if flow cytometry is the intended answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks for the \\\"most specific\\\" test for Kufs disease (adult NCL), but the clinical vignette describes features atypical for Kufs disease. Classic Kufs disease (CLN4) presents with myoclonus and seizures but typically lacks visual loss and cerebellar ataxia, which are hallmarks of juvenile NCL (CLN3). The vignette's phenotype better fits juvenile or late-infantile NCL, not adult-onset Kufs. This creates ambiguity about which NCL subtype is being tested. For typical Kufs disease, genetic testing (CLN6, CTSF, DNAJC5) is now the gold standard, making option A (epilepsy gene panel) partially relevant if it included NCL genes. Skin biopsy with EM (option C) has variable sensitivity in Kufs disease—some subtypes show minimal peripheral deposits. Brain biopsy (option B) remains definitive for Kufs when skin biopsy is negative. The stem's phenotypic mismatch with Kufs disease makes it impossible to determine whether the question intends to test knowledge of (1) classic Kufs diagnosis (favoring genetic testing or brain biopsy) or (2) general NCL diagnosis (favoring skin EM). Medical accuracy issues: conflating different NCL subtypes; overstating skin biopsy specificity for Kufs. Minimal fix: Revise clinical features to match typical Kufs presentation (myoclonus, dementia, NO visual loss) or clarify NCL subtype in the question stem.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks for the \"most specific\" test for Kufs disease (adult NCL), but the clinical vignette describes features atypical for Kufs disease. Classic Kufs disease (CLN4) presents with myoclonus and seizures but typically lacks visual loss and cerebellar ataxia, which are hallmarks of juvenile NCL (CLN3). The vignette's phenotype better fits juvenile or late-infantile NCL, not adult-onset Kufs. This creates ambiguity about which NCL subtype is being tested. For typical Kufs disease, genetic testing (CLN6, CTSF, DNAJC5) is now the gold standard, making option A (epilepsy gene panel) partially relevant if it included NCL genes. Skin biopsy with EM (option C) has variable sensitivity in Kufs disease—some subtypes show minimal peripheral deposits. Brain biopsy (option B) remains definitive for Kufs when skin biopsy is negative. The stem's phenotypic mismatch with Kufs disease makes it impossible to determine whether the question intends to test knowledge of (1) classic Kufs diagnosis (favoring genetic testing or brain biopsy) or (2) general NCL diagnosis (favoring skin EM). Medical accuracy issues: conflating different NCL subtypes; overstating skin biopsy specificity for Kufs. Minimal fix: Revise clinical features to match typical Kufs presentation (myoclonus, dementia, NO visual loss) or clarify NCL subtype in the question stem.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}]